Alaunos Therapeutics (Alaunos Therapeutics) Price-to-Operating-Cash-Flow : (As of Apr. 25, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-04-25), Alaunos Therapeutics's share price is $1.16. Alaunos Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.88. Hence, Alaunos Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Alaunos Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Alaunos Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 179.63. The lowest was 105.81. And the median was 145.28.

TCRT's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.7
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Alaunos Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.46. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.88.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -90.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -53.10% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -38.10% per year.

During the past 13 years, Alaunos Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 96.00% per year. The lowest was -1628.20% per year. And the median was 8.95% per year.

Alaunos Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Alaunos Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Price-to-Operating-Cash-Flow Chart

Alaunos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Alaunos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Alaunos Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Alaunos Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alaunos Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Price-to-Operating-Cash-Flow falls into.

Alaunos Therapeutics Price-to-Operating-Cash-Flow Calculation

Alaunos Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.16	/	-1.884
	=

Alaunos Therapeutics's Share Price of today is $1.16.
Alaunos Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.88.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Alaunos Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Alaunos Therapeutics (Alaunos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

8030 El Rio Street, Houston, TX, USA, 77054

Website

https://www.alaunos.com

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Executives

Boyle Kevin S. Sr.	director, officer: Chief Executive Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister	director	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser	director	ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma	director	141 MECOX ROAD, WATER MILL NY 11976
Michael Wong	officer: VP, Finance	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava	officer: See Remarks	C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis	director	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden	director	38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle	director	C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger	officer: VP, Research & Development	C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De	officer: EVP, Operations	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey	officer: Senior Vice President, Legal	C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen	director	AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa	officer: Chief Medical Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129